Premium
P1‐300: The relationship between cerebral spinal fluid (CSF) biomarkers and Pittsburgh Compound B (PiB) positron emission tomography (PET) in predicting Alzheimer's disease (AD)
Author(s) -
Burns Leah,
Berman Robert,
Guo Zhenchao,
Soares Holly,
Kaplita Stephen,
Yoo Bongin,
Donohue Michael
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.579
Subject(s) - pittsburgh compound b , positron emission tomography , medicine , nuclear medicine , standardized uptake value , cognitive impairment , neuroimaging , dementia , cerebrospinal fluid , oncology , disease , psychiatry
support evidence-based decisions for an internationally harmonized protocol. A harmonized procedure is required, since quantitative MRI should help diagnosis and tracking of AD. A survey of segmentation protocols allowed to operationalize the landmarks variability into segmentation units (SUs) (Figure), and their impact on volume estimates has been preliminarily quantified. Methods: A power analysis was carried out on a preliminary sample, to define the sample size allowing reliable computation. Then, we manually traced each SU within the right and left hippocampi of a larger sample of Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants, which included Mild Cognitive Impairment (MCI) patients who subsequently converted to AD and AD patients, all with abnormal Cerebrospinal Fluid (CSF) Aß levels, and controls (CTRL), with normal CSF Aß levels. Results: The power analysis indicated a required sample size for the quantification of SUs impact on AD-related volume differences of n 1⁄4 77 (31 CTRL, 23 MCI, 23 AD). So far, 40 subjects (16 CTRL, 12 MCI, 12 AD) have been traced and analyzed. The minimum hippocampal body (red SU in Figure) accounted for over 62% of AD-related volume difference across groups (left: 68.5%, right: 62%, p<0.001); the left alveus/ fimbria (yellow SU in Figure) for 7.5% (p 1⁄4 0.01) and the right alveus/fimbria for 3% (p1⁄4 0.7); the subiculum (green SUs in Figure) for 5% bilaterally (left: p1⁄4 0.08; right: p1⁄4 0.03); the left tail (blue SUs in Figure) for 19% (p 1⁄4 0.003), and the right tail for the 30% (p 1⁄4 0.001) of the global difference across groups. Conclusions: The informative value for identifying AD-related atrophy differs across SUs. Its quantification may help a panel of experts to define which SU should be included in a harmonized protocol.